E
ALZN icon

Ergoteles’s Alzamend Neuro ALZN Stock Holding History

Ergoteles’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17
Closed -$13.3K – 1216
2022
Q4 		$13.3K Buy
+17
New +$24.6K ﹤0.01% 1362

Other funds holding ALZN

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ergoteles's ALZN Position: Q1 2023 in Review

Ergoteles sold out of Alzamend Neuro (ALZN) in Q1 2023, closing a stake of 17 shares — an estimated $13.3K sold.

Ergoteles first reported a position in ALZN in Q4 2022 and held it in 1 quarter. The position peaked at $13.3K in Q4 2022. 24 funds tracked by Wall St. Rank hold ALZN as of Q1 2023.

  • Ergoteles reported no remaining Alzamend Neuro position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 17 Alzamend Neuro shares in Q1 2023, an estimated $13.3K.
  • Ergoteles first reported a position in Alzamend Neuro in Q4 2022 and held it in 1 quarter.
  • Ergoteles's Alzamend Neuro position peaked at $13.3K in Q4 2022.
  • 24 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.